Date Title Description PDF
04 Nov 2022 On business and financial situation The Company releases the first nine months 2022 financial results presentation Download
15 Mar 2022 On significant placements in financial instruments Bestinver announces details of an accelerated book building process of approximately 5% of the share capital of Laboratorios Farmacéuticos Rovi, S.A. Download
14 Mar 2022 On significant placements in financial instruments Bestinver announces the beginning of an accelerated book building process approximately 5% of the share capital of Laboratorios Farmacéuticos Rovi, S.A. Download
23 Feb 2022 On business and financial situation The Company releases the press release related to the full year 2021 financial results Download
23 Feb 2022 On business and financial situation The Company releases the full year 2021 financial results presentation Download

Pages

Date Title Description PDF
26 Jan 2024 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 19 January and 25 January 2024 Download
19 Jan 2024 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 12 January and 18 January 2024 Download
12 Jan 2024 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 5 January and 11 January 2024 Download
05 Jan 2024 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 29 December 2023 and 4 January 2024 Download
29 Dec 2023 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 22 December and 28 December 2023 Download

Pages

Date Title Description PDF
26 Feb 2019 Información sobre resultados ROVI releases the presentation related to the full year 2018 results Download
26 Feb 2019 Información sobre resultados ROVI releases the press release related to the full year 2018 results Download
15 Feb 2019 Others on business performance and financial information ROVI acquires rights to Dexchlorpheniramine Maleate in the Spanish and French markets Download
09 Jan 2019 Others on business performance and financial information ROVI informs about the adquisition of Falithrom® for the German market Download
08 Jan 2019 Liquidity contracts and specialists Liquidity contract: transactions conducted in the fourth quarter of 2018 Download

Pages